Aberrant histone modification in CD19⁺ B cells of patients with chronic lymphocytic leukemia

Area of Science:

• * Molecular Biology
• * Cancer Research
• * Epigenetics

Background:

• * Chronic lymphocytic leukemia (CLL) is a B-cell malignancy characterized by the accumulation of malignant lymphocytes.
• * Epigenetic alterations, including histone modifications, are increasingly recognized as key drivers in cancer development and progression.

Purpose of the Study:

• * To investigate global histone H3/H4 acetylation and H3K4/H3K9 methylation patterns in patients with CLL.
• * To assess the mRNA expression of key chromatin-modifying enzymes in CLL B cells.
• * To correlate these epigenetic changes with disease stage and risk stratification.

Main Methods:

• * Global histone acetylation and methylation levels were quantified using specialized assay kits.
• * Messenger RNA (mRNA) expression of chromatin modifier genes (SIRT1, EZH2, HDAC1, HDAC2, HDAC7, P300) was measured via real-time polymerase chain reaction (RT-PCR).
• * Statistical analyses were performed to compare epigenetic profiles between CLL patients and controls, and across different disease stages.

Main Results:

• * CLL patients exhibited global histone H3/H4 hypoacetylation and increased H3K9 methylation in CD19+ B cells compared to healthy controls.
• * mRNA levels of SIRT1 and EZH2 were significantly upregulated in CLL patients, correlating with advanced Binet and Rai stages.
• * Expression of HDAC1 and HDAC7 mRNA was elevated, while HDAC2 and P300 mRNA levels were reduced in CLL patients.

Conclusions:

• * Aberrant histone modifications, including hypoacetylation and specific methylation patterns, are prevalent in chronic lymphocytic leukemia.
• * Upregulation of SIRT1 and EZH2, along with altered HDAC and P300 expression, suggests their critical role in CLL pathogenesis and progression.
• * These findings highlight the potential of targeting epigenetic machinery for therapeutic strategies in CLL.